Clinical Trials
32 trials18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
TraveraRTGx
Travera Inc
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
ETCABIO
University Hospital, Angers
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
ACROPOLI
SOLTI Breast Cancer Research Group
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
ICEMELT
Western Sydney Local Health District
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
REGOMUNE
Institut Bergonié
DUET-2
Xencor, Inc.
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
MT2004-30: Tomotherapy for Solid Tumors
Masonic Cancer Center, University of Minnesota
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
National Cancer Institute (NCI)